✦ LIBER ✦

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

✍ Scribed by Rummel, M. J.

Book ID: 123612910
Publisher: American Society of Clinical Oncology
Year: 2005
Tongue: English
Weight: 282 KB
Volume: 23
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2005.08.100

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduced-dose cladribine (2-CdA) plus mit

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

✍ M.J Rummel; K.U Chow; T Karakas; E Jäger; J Mezger; U von Grünhagen; K.-P Schalk 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Cost-Effectiveness Of Bendamustine+Ritux

Cost-Effectiveness Of Bendamustine+Rituximab Versus Fludarabine+Rituximab In The Treatment Of Relapsed Indolent Non-Hodgkin's And Mantle Cell Lymphomas In Canada

✍ Lachaine, J.; Beauchemin, C.; Mathurin, K.; Aissa, F. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB

Results of a Phase II Multicenter Trial

Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen

✍ Drapkin, Robert; Di Bella, Nicholas J.; Faragher, David C.; Harden, Elizabeth; M 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 165 KB

Randomized phase III study for the treat

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

✍ M. Herold; G. Dölken; F. Fiedler; A. Franke; M. Freund; W. Helbig; R. Pasold 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 131 KB

Combined cyclophosphamide, vincristine,

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group

✍ Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Tr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

## Abstract ## BACKGROUND. In patients with advanced‐stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades. ## METHODS. The German Low‐Grade Lymphom